InMed Pharmaceuticals (INM) Competitors $2.32 +0.10 (+4.50%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$2.30 -0.02 (-0.86%) As of 09/16/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INM vs. EDSA, LSB, THAR, IBIO, CLRB, MTVA, AIMD, MTEX, IXHL, and LPCNShould you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Edesa Biotech (EDSA), LakeShore Biopharma (LSB), Tharimmune (THAR), iBio (IBIO), Cellectar Biosciences (CLRB), MetaVia (MTVA), Ainos (AIMD), Mannatech (MTEX), Incannex Healthcare (IXHL), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. InMed Pharmaceuticals vs. Its Competitors Edesa Biotech LakeShore Biopharma Tharimmune iBio Cellectar Biosciences MetaVia Ainos Mannatech Incannex Healthcare Lipocine InMed Pharmaceuticals (NASDAQ:INM) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability. Which has preferable earnings and valuation, INM or EDSA? Edesa Biotech has lower revenue, but higher earnings than InMed Pharmaceuticals. Edesa Biotech is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInMed Pharmaceuticals$4.60M1.01-$7.68M-$12.09-0.19Edesa BiotechN/AN/A-$6.17M-$1.32-1.86 Which has more risk & volatility, INM or EDSA? InMed Pharmaceuticals has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Do analysts recommend INM or EDSA? Edesa Biotech has a consensus target price of $5.00, suggesting a potential upside of 103.25%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Edesa Biotech is more favorable than InMed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Is INM or EDSA more profitable? Edesa Biotech has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -168.87%. InMed Pharmaceuticals' return on equity of -107.93% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets InMed Pharmaceuticals-168.87% -107.93% -82.97% Edesa Biotech N/A -162.95%-60.33% Do insiders & institutionals have more ownership in INM or EDSA? 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 1.4% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 22.6% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to INM or EDSA? In the previous week, InMed Pharmaceuticals had 4 more articles in the media than Edesa Biotech. MarketBeat recorded 5 mentions for InMed Pharmaceuticals and 1 mentions for Edesa Biotech. InMed Pharmaceuticals' average media sentiment score of 1.29 beat Edesa Biotech's score of 0.95 indicating that InMed Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment InMed Pharmaceuticals Positive Edesa Biotech Positive SummaryEdesa Biotech beats InMed Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INM vs. The Competition Export to ExcelMetricInMed PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.44M$2.55B$5.73B$10.31BDividend YieldN/A60.31%5.90%4.63%P/E Ratio-0.1923.4976.3926.51Price / Sales1.01672.77527.15123.58Price / CashN/A169.4937.1760.46Price / Book0.115.3313.306.29Net Income-$7.68M$32.95M$3.28B$270.51M7 Day Performance6.91%0.10%0.88%1.95%1 Month PerformanceN/A3.91%4.67%6.33%1 Year Performance-54.92%-3.91%76.59%25.62% InMed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMInMed Pharmaceuticals1.2518 of 5 stars$2.32+4.5%N/A-53.9%$4.44M$4.60M-0.1910News CoveragePositive NewsShort Interest ↓High Trading VolumeEDSAEdesa Biotech1.4342 of 5 stars$2.44+0.8%$5.00+104.9%-41.6%$17.18MN/A-1.8520Gap UpLSBLakeShore Biopharma1.2174 of 5 stars$0.83-1.2%N/A-88.8%$16.89M$85.67M0.00773Short Interest ↓Gap UpTHARTharimmune2.4562 of 5 stars$2.97+0.2%$17.00+473.4%+0.7%$16.87MN/A-0.492IBIOiBio1.6802 of 5 stars$0.85-0.8%$5.00+489.6%-56.1%$16.67M$375K-0.49100Short Interest ↑CLRBCellectar Biosciences3.5013 of 5 stars$5.23+3.9%$375.00+7,075.7%-91.8%$16.65MN/A-0.2610Short Interest ↓MTVAMetaVia2.3698 of 5 stars$0.69-0.4%$7.50+991.7%N/A$16.63MN/A0.008Gap DownAIMDAinos1.4004 of 5 stars$3.54-1.9%N/A+37.5%$16.50M$20K-0.7140News CoveragePositive NewsMTEXMannatech0.9771 of 5 stars$8.68-7.4%N/A+8.7%$16.48M$117.87M-4.25250Short Interest ↓IXHLIncannex Healthcare0.1481 of 5 stars$0.56-4.6%N/A-69.0%$16.25M$10K-0.463Short Interest ↑LPCNLipocine3.3296 of 5 stars$2.94+1.0%$9.00+206.1%-37.9%$15.93M$4.21M-3.3810 Related Companies and Tools Related Companies EDSA Alternatives LSB Alternatives THAR Alternatives IBIO Alternatives CLRB Alternatives MTVA Alternatives AIMD Alternatives MTEX Alternatives IXHL Alternatives LPCN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INM) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INM Stock Alerts